Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952110 | 0.88 | GLA (0.59) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL2947983 | 0.88 | GLA (0.64) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL20885121 | 0.84 | ALDH1A1 (0.56) | LMNAALDH1A1SMN1; SMN2USP2HSD17B10 | |
| SCHEMBL9415751 | 0.82 | GLA (0.67) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL12888081 | 0.81 | TSHR (0.61) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL6233242 | 0.81 | TSHR (0.56) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL7347977 | 0.81 | POLB (0.56) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL3404224 | 0.80 | L3MBTL1 (0.63) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL7694058 | 0.80 | GLA (0.65) | POLBTSHRLMNAFKBP1AALDH1A1 | |
| SCHEMBL7380670 | 0.80 | L3MBTL1 (0.57) | POLBTSHRLMNAFKBP1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-119143631-A | Deprotection method for peptide compound or amide compound and resin removal method in solid phase reaction and method for producing peptide compound | 中外制药株式会社 | 2024-12-17 | — | — | CN | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| EP-0470702-B1 | An optically active morpholino oxobutyric acid hydroxy binaphthalene derivative and its preparation | TAKASAGO PERFUMERY CO LTD (JP) | 1995-09-27 | — | — | EP | claimed |
| EP-0470702-A1 | An optically active morpholino oxobutyric acid hydroxy binaphthalene derivative and its preparation | Takasago International Corporation (JP) | 1992-02-12 | — | — | EP | claimed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| CN-119143631-A | Deprotection method for peptide compound or amide compound and resin removal method in solid phase reaction and method for producing peptide compound | 中外制药株式会社 | 2024-12-17 | — | — | CN | disclosed |
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | iTeos Belgium SA (BE) | 2024-11-07 | — | — | US | disclosed |
| EP-0470702-A1 | An optically active morpholino oxobutyric acid hydroxy binaphthalene derivative and its preparation | Takasago International Corporation (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0383635-A2 | Peptides having renin inhibitory activity their preparation and use | Sankyo Company Limited (JP) | 1990-08-22 | — | — | EP | disclosed |
| US-4826815-A | HYPOTENSIVE | ABBOTT LABORATORIES (US) | 1989-05-02 | — | — | US | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0010941-B1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-12 | — | — | EP | disclosed |
| EP-0010941-A1 | 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368183-A1 | Macrocyclic Compounds Having ENT1 Inhibiting Activity | ENTPD5, ENTPD1, ENTPD8 | POLB 2774/4885TSHR 2322/4885LMNA 2132/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | POLB 1910/4885TSHR 778/4885LMNA 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.